InsiderTrades

Form 4 for CGEM Cullinan Therapeutics, Inc.

Accepted 2023-06-08 00:00:00 ET · period of report 2023-06-06 · accession 0000950170-23-027063 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2023-06-08 2023-06-06+ CGEM Michaelson Jennifer Chief Development Off M - OptEx $4.30 +12.0K 90.5K +15% +$51.6K
DMT 2023-06-08 2023-06-06+ CGEM Michaelson Jennifer Chief Development Off S - Sale+OE $12.31 -12.0K 90.4K -12% -$147.7K
DMT 2023-06-08 2023-06-06+ CGEM Michaelson Jennifer Chief Development Off M - OptEx $0.00 -12.0K 188.7K -6% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-06-06 M A 11,900 $4.30 102,347 D — —
2 Common Common Stock 2023-06-06 S D 11,900 $12.31 90,447 D — — (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.30 to $12.35. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3 Common Common Stock 2023-06-07 S D 100 $12.40 90,447 D — —
4 Common Common Stock 2023-06-07 M A 100 $4.30 90,547 D — —
5 Derivative Stock Option (Right to Buy) 2023-06-07 M D 100 $0.00 188,593 D $4.30 · — to 2030-10-28 100 Common Stock (F3) 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
6 Derivative Stock Option (Right to Buy) 2023-06-06 M D 11,900 $0.00 188,693 D $4.30 · — to 2030-10-28 11,900 Common Stock (F3) 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.